Troglitazone in Treating Patients With Liposarcoma

Completed · Phase 2

Conditions studied: Sarcoma

In brief

Troglitazone may help liposarcoma cells develop into normal cells. This was a single arm, open-label study with a two-stage design to evaluate troglitazone in patients with liposarcoma stratified by histologic subtype.

Key facts

Study ID

NCT00003058

Run by

Dana-Farber Cancer Institute

People needed

85

Starts

1997-06-01

Expected to finish

2000-01-01

Last updated by the study team

2017-02-13

Who can join

Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Brigham and Women's Hospital — Boston, Massachusetts, United States
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.